Allan J. Bream

CRB
Senior Fellow, Biopharmaceutical Process, Associate
Allan Bream has more than 30 years of engineering and manufacturing experience, including 25 years in the biotechnology industry. His expertise includes large-scale bacterial fermentation, mammalian cell culture, vaccines, downstream processing, protein purification and immobilization and Current Good Manufacturing Practice facility design, operations and assessment. Bream’s facilities experience includes all phases of process design, including master planning, conceptual and detailed design, construction services and equipment procurement across the United States, Puerto Rico, Europe and Asia. His experience also includes biosafety level 2 and biosafety level 3 facility design projects. He has also worked in corporate engineering, process development and biomanufacturing positions for Chiron Corp. and Baxter Healthcare. Bream has a Master of Science in biochemical engineering and a Bachelor of Science in chemical engineering from the University of Iowa.

Related Articles

Figure 1: Experts were asked “Do you see any of the following as a weak point in successful cell therapy manufacturing.”
Technical
Using Industry Survey Data to Shape Cell Therapy Facility Design

Cell therapies have been used to treat thousands of patients worldwide ever since the CAR T cell medication Kymriah was the first cell therapy approved by the FDA in 2017.  Yet significant manufacturing challenges continue to hamper patient access to life-saving cell therapies, particularly the high cost of these treatments. Kymriah can cost as much as $475,000 per dose and an allogeneic...